TLR Agonists as Adjuvants for Cancer Vaccines

  • Ji-Kun Li
  • Jesse J. Balic
  • Liang YuEmail author
  • Brendan Jenkins
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1024)


Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.


Toll-like receptor Agonist Adjuvant Clinical trial 


  1. 1.
    Gay NJ, Gangloff M (2007) Structure and function of toll receptors and their ligands. Annu Rev Biochem 76(1):141–165PubMedCrossRefGoogle Scholar
  2. 2.
    Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21(1):335–376PubMedCrossRefGoogle Scholar
  3. 3.
    Janeway CA (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54:1–13PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Hernandez C, Huebener P, Schwabe RF (2016) Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35(46):5931–5941PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Kadowaki N et al (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194(6):863–870PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Adams S (2009) Toll-like receptor agonists in cancer therapy. Immunotherapy 1(6):949–964PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Hayashi F, Means TK, Luster AD (2003) Toll-like receptors stimulate human neutrophil function. Blood 102(7):2660–2669PubMedCrossRefGoogle Scholar
  8. 8.
    Peng G et al (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309(5739):1380–1384PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Alison CW, Brendan JJ (2015) Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer. Curr Pharm Des 21(21):2968–2977CrossRefGoogle Scholar
  10. 10.
    Kovach MA, Standiford TJ (2011) Toll like receptors in diseases of the lung. Int Immunopharmacol 11(10):1399–1406PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    LaRue H et al (2013) Toll-like receptors in urothelial cells—targets for cancer immunotherapy. Nat Rev Urol 10(9):537–545PubMedCrossRefGoogle Scholar
  12. 12.
    Paulos CM et al (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13(18):5280–5289PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Dowling JK, Mansell A (2016) Toll-like receptors: the Swiss army knife of immunity and vaccine development. Clin Translat Immunol 5(5):e85CrossRefGoogle Scholar
  14. 14.
    Human Papillomavirus (HPV) Vaccines. National Cancer Institute (NCI) (2009). 2009–10-22 (Retrieved 2009–11–11)Google Scholar
  15. 15.
    Hepatitis B vaccines WHO position paper. Weekly epidemiological record (2009) 40(84):405–420Google Scholar
  16. 16.
    Silva A et al (2015) The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol 194(5):2199–2207PubMedCrossRefGoogle Scholar
  17. 17.
    Vasilakos JP, Tomai MA (2013) The use of toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 12(7):809–819PubMedCrossRefGoogle Scholar
  18. 18.
    Mutwiri G et al (2011) Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines 10(1):95–107PubMedCrossRefGoogle Scholar
  19. 19.
    Martins KAO, Bavari S, Salazar AM (2015) Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines 14(3):447–459PubMedCrossRefGoogle Scholar
  20. 20.
    Banday AH, Jeelani S, Hruby VJ (2015) Cancer vaccine adjuvants – recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 37(1):1–11PubMedCrossRefGoogle Scholar
  21. 21.
    Walter A et al (2013) Aldara activates TLR7-independent immune defence. Nat Commun 4:1560PubMedCrossRefGoogle Scholar
  22. 22.
    Spaner DE et al (2009) A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24(1):222–226PubMedCrossRefGoogle Scholar
  23. 23.
    Jasani B, Navabi H, Adams M (2009) Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27(25–26):3401–3404PubMedCrossRefGoogle Scholar
  24. 24.
    Vacchelli E et al (2012) Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. OncoImmunology 1(6):894–907PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Galluzzi L et al (2012) Trial watch: experimental toll-like receptor agonists for cancer therapy. OncoImmunology 1(5):699–739PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Brackett CM et al (2016) Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci 113(7):E874–E883PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Musch E et al (2013) Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 19(2):283–292PubMedCrossRefGoogle Scholar
  28. 28.
    Dalgleish AG et al (2016) Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 115(7):789–796PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Smith DA et al (2014) Antitumor activity and safety of combination therapy with the toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunol Immunother 63(8):787–796PubMedCrossRefGoogle Scholar
  30. 30.
    Friedberg JW et al (2009) Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 146(3):282–291PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Isambert N et al (2013) Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 13(1):172PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Vacchelli E et al (2013) Trial watch: toll-like receptor agonists for cancer therapy. OncoImmunology 2(8):e25238PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Wang S et al (2016) Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci 113(46):E7240–E7249PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Donin NM et al (2017) A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol Semin Orig Investig 35(2):39.e1–39.e7CrossRefGoogle Scholar
  35. 35.
    Lu H et al (2012) VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 18(2):499–509PubMedCrossRefGoogle Scholar
  36. 36.
    Mount A et al (2013) Combination of adjuvants: the future of vaccine design. Expert Rev Vaccines 12(7):733–746PubMedCrossRefGoogle Scholar
  37. 37.
    Hughes AL, Piontkivska H (2008) Functional diversification of the Toll-like receptor gene family. Immunogenetics 60(5):249–256PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Roach JC et al (2005) The evolution of vertebrate toll-like receptors. Proc Natl Acad Sci U S A 102(27):9577–9582PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Dowling JK, Dellacasagrande J (2016) Toll-like receptors: ligands, cell-based models, and readouts for receptor action. In: McCoy CE (ed) Toll-like receptors: practice and methods. Springer, New York, pp 3–27CrossRefGoogle Scholar
  40. 40.
    Murata M (2008) Activation of toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium Bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 99(7):1435–1440PubMedCrossRefGoogle Scholar
  41. 41.
    Netea MG et al (2004) Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 172(6):3712–3718PubMedCrossRefGoogle Scholar
  42. 42.
    Sun X et al (2013) TLR2 mediates helicobacter pylori–induced Tolerogenic immune response in mice. PLoS One 8(9):e74595PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Yamazaki S et al (2011) TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 Lipopeptides in vivo. PLoS One 6(4):e18833PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Nyirenda MH et al (2015) TLR2 stimulation regulates the balance between regulatory T cell and Th17 function: a novel mechanism of reduced regulatory T cell function in multiple sclerosis. J Immunol 194(12):5761–5774PubMedCrossRefGoogle Scholar
  45. 45.
    McCartney S et al (2009) Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 206(13):2967–2976PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Mitchell WM (2016) Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol 9(6):755–770PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Caskey M et al (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208(12):2357–2366PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Lampkin BC et al (1985) Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-l-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and Neuroblastoma: a report from the Children’s cancer study group. Cancer Res 45(11 Part 2):5904–5909PubMedPubMedCentralGoogle Scholar
  49. 49.
    Sabbatini P et al (2012) Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18(23):6497–6508PubMedCrossRefGoogle Scholar
  50. 50.
    Tsuji T et al (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1(5):340–350PubMedCrossRefGoogle Scholar
  51. 51.
    Takeoka T et al (2017) NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC. J Immunother 40(4):140–147CrossRefGoogle Scholar
  52. 52.
    Okada H et al (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade Glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21(2):286–294PubMedCrossRefGoogle Scholar
  53. 53.
    Chen T et al (2009) Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol 182(3):1449–1459PubMedCrossRefGoogle Scholar
  54. 54.
    Apetoh L et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059PubMedCrossRefGoogle Scholar
  55. 55.
    Cluff CW (2013) Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Austin: Landes Bioscience, p 2000–2013Google Scholar
  56. 56.
    Talat Iqbal N, Hussain R (2014) Non-specific immunity of BCG vaccine: A perspective of BCG immunotherapy. Trials in Vaccinology 3:143–149CrossRefGoogle Scholar
  57. 57.
    Coleman MM, Keane J, Mills KHG (2010) Editorial: Tregs and BCG—dangerous liaisons in TB. J Leukoc Biol 88(6):1067–1069PubMedCrossRefGoogle Scholar
  58. 58.
    Ovchinnikova OA et al (2014) Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J Intern Med 275(1):49–58PubMedCrossRefGoogle Scholar
  59. 59.
    Iribarren K et al (2016) Trial watch: Immunostimulation with toll-like receptor agonists in cancer therapy. OncoImmunology 5(3):e1088631PubMedCrossRefGoogle Scholar
  60. 60.
    Sato T et al (2016) M1 macrophage infiltrations and histological changes in the liver after portal vein embolization using fibrinogen and OK432 in the rat. Cell Immunol 303:66–71PubMedCrossRefGoogle Scholar
  61. 61.
    Kenjo A et al (2016) Role of intratumoral infiltrating macrophages after transarterial immunoembolization for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 23(5):298–304PubMedCrossRefGoogle Scholar
  62. 62.
    Wada H et al (2014) Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 Antigen. J Immunother 37(2):84–92PubMedCrossRefGoogle Scholar
  63. 63.
    Lambert SL et al (2012) Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl lipid A. PLoS One 7(12):e51618PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Lu H, Jan ter Meulen JH (2016) Intratumoral injection of G100 (TLR4 agonist glucopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity AACR Annual Meeting, p 4885Google Scholar
  65. 65.
    Matzner P et al (2016) Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects. Int J Cancer 138(7):1754–1764PubMedCrossRefGoogle Scholar
  66. 66.
    SID B, Vandeven N et al (2015) Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC). ASCO Meeting 33:3083Google Scholar
  67. 67.
    Faham A, Altin JG (2010) Antigen-containing liposomes engrafted with Flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol 185(3):1744–1754PubMedCrossRefGoogle Scholar
  68. 68.
    Sfondrini L et al (2006) Antitumor activity of the TLR-5 ligand Flagellin in mouse models of cancer. J Immunol 176(11):6624–6630PubMedCrossRefGoogle Scholar
  69. 69.
    Garaude J et al (2012) Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 4(120):120ra16–120ra16.PubMedCrossRefGoogle Scholar
  70. 70.
    Cai Z et al (2011) Activation of Toll-like receptor 5 on breast cancer cells by Flagellin suppresses cell proliferation and tumor growth. Cancer Res 71(7):2466–2475PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Yang H et al (2016) The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget 7(3):2936–2950PubMedGoogle Scholar
  72. 72.
    Fukuzawa N et al (2011) A TLR5 agonist inhibits acute renal ischemic failure. J Immunol 187(7):3831–3839PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Xu Y et al (2016) CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation. Ann Trans Med 4(16):301CrossRefGoogle Scholar
  74. 74.
    Burdelya LG et al (2008) An agonist of toll-like receptor 5 has Radioprotective activity in mouse and primate models. Science 320(5873):226–230PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Burdelya LG et al (2013) Central role of liver in anticancer and radioprotective activities of toll-like receptor 5 agonist. Proc Natl Acad Sci 110(20):E1857–E1866PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Reeh M et al (2013) Presence of the Coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer 109(7):1848–1858PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Diebold SS et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663):1529–1531PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Wille-Reece U et al (2005) HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 102(42):15190–15194PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33(4):492–503PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Tomai MA, Vasilakos JP (2011) TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev Vaccines 10(4):405–407PubMedCrossRefGoogle Scholar
  81. 81.
    Adams S et al (2012) Topical TLR7 agonist Imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 18(24):6748–6757PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Bath-Hextall F et al (2014) Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15(1):96–105PubMedCrossRefGoogle Scholar
  83. 83.
    Bassukas ID, Gaitanis G (2014) Basal-cell carcinoma: no response versus relapse. Lancet Oncol 15(3):e104–e105PubMedCrossRefGoogle Scholar
  84. 84.
    Lear JT (2014) Evidence-based treatment for low-risk basal cell carcinoma. Lancet Oncol 15(1):12–13PubMedCrossRefGoogle Scholar
  85. 85.
    Sabado RL et al (2015) Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res 3(3):278–287PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Smirnov D et al (2011) Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29(33):5434–5442PubMedCrossRefGoogle Scholar
  87. 87.
    Abhyankar MM et al (2017) Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine 35(6):916–922PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Singh M et al (2014) Effective innate and adaptive Antimelanoma immunity through localized TLR7/8 activation. J Immunol 193(9):4722–4731PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Kapp K et al (2016) Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context. Immun Inflammation Dis 4(4):446–462CrossRefGoogle Scholar
  90. 90.
    Yang B et al (2014) DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 10(11):3153–3164PubMedCrossRefGoogle Scholar
  91. 91.
    Hirsh V et al (2011) Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non–small-cell lung cancer. J Clin Oncol 29(19):2667–2674PubMedCrossRefGoogle Scholar
  92. 92.
    Manegold C et al (2012) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23(1):72–77PubMedCrossRefGoogle Scholar
  93. 93.
    Wittig B et al (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol/Hematol 94(1):31–44CrossRefGoogle Scholar
  94. 94.
    Schmoll HJ, Riera-Knorrenschild J, Kopp HG et al (2015) Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: a subgroup with improved overall survival. J Clin Oncol 33(suppl 3):abstr 680CrossRefGoogle Scholar
  95. 95.
    Schmoll H-J et al (2014) Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol 140(9):1615–1624PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Cunningham D, Zurlo A, Salazar R et al (2015) IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703. J Clin Oncol 33(suppl 3):abstr TPS791CrossRefGoogle Scholar
  97. 97.
    Houot R, Levy R (2009) T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113(15):3546–3552PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Marabelle A, Kohrt H, Levy R (2013) Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 19(19):5261–5263PubMedCrossRefGoogle Scholar
  99. 99.
    Barrett DM et al (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65(1):333–347PubMedCrossRefGoogle Scholar
  100. 100.
    Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Dajon M, Iribarren K, Cremer I (2017) Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology 222(1):89–100PubMedCrossRefGoogle Scholar
  102. 102.
    Lu H (2014) TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects. Front Immunol 5:83PubMedPubMedCentralGoogle Scholar
  103. 103.
    Beswick EJ et al (2014) TLR4 activation enhances the PD-L1–mediated Tolerogenic capacity of colonic CD90+ stromal cells. J Immunol 193(5):2218–2229PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Boes M, Meyer-Wentrup F (2015) TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer Lett 361(1):49–56PubMedCrossRefGoogle Scholar
  105. 105.
    Wang R-F, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27(1):11–37PubMedCrossRefGoogle Scholar
  106. 106.
    Mullard A (2016) The cancer vaccine resurgence. Nat Rev Drug Discov 15(10):663–665PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  • Ji-Kun Li
    • 1
  • Jesse J. Balic
    • 2
    • 3
  • Liang Yu
    • 1
    • 2
    • 3
    Email author
  • Brendan Jenkins
    • 2
    • 3
  1. 1.Department of General Surgery, Shanghai Jiao Tong University Affiliated First People’s HospitalShanghai Jiao Tong UniversityShanghaiChina
  2. 2.Centre for Innate Immunity and Infectious DiseasesHudson Institute of Medical ResearchClaytonAustralia
  3. 3.Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health SciencesMonash UniversityClaytonAustralia

Personalised recommendations